Company Overview - Pyxis Oncology, Inc. is a clinical-stage company focused on developing antibody-drug conjugate (ADC) therapeutics for difficult-to-treat cancers [1][2] - The company is building therapeutics that have potential for both monotherapy and combination indications [2] Lead Candidate - The lead candidate, micvotabart pelidotin (MICVO), is currently being evaluated in ongoing Phase 1 clinical studies targeting multiple types of solid tumors [2] - The development focus is on treating patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) due to promising signals observed in this area [2] - A Phase 1/2 combination study of MICVO and Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), has been initiated for patients with R/M HNSCC and other advanced solid tumors [2] Upcoming Conferences - Lara S. Sullivan, M.D., President and CEO, will participate in several upcoming investor conferences, including: - 2025 Cantor Global Healthcare Conference on September 3, 2025, featuring a fireside chat and investor one-on-one meetings [4] - H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025, also including a fireside chat and investor one-on-one meetings [4] - 2nd Annual ADC and Novel Conjugates Partnering and Investment Summit on September 9, 2025, with a company presentation [1][4]